Skip to main content
Download PDF

Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma

BMC Cancer volume 24, Article number: 249 (2024) Cite this article

Abstract

Background

Increasing evidence has showed that inflammatory biomarkers, including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and fibrinogen can be used as predictors in the prognosis of esophageal squamous cell carcinoma (ESCC). The aim of this study was to explore prognostic value of these biomarkers and evaluate the clinicopathological and prognostic significance of combined score based on plasma fibrinogen and platelet-lymphocyte ratio (F-PLR score).

Methods

A total of 506 patients with ESCC were enrolled in this study. Harrell’s concordance index (c-index) was used to determine the optimal cut-off values of these markers and evaluate their prognostic significance. The relationship between factors with survival rates (including overall survival [OS] and disease-free survival [DFS]) was explored by Kaplan-Meier curve, univariate analysis and multivariate cox hazard analysis.

Results

Our result indicated that high F-PLR score was significantly associated with longer tumor length and deeper depth of tumor invasion (p < 0.01). The result of Cox multivariable analysis showed that F-PLR score was an independent prognostic factor for OS (p = 0.002) and DFS (p = 0.003). In addition, F-PLR score presented the greater c-index values for OS and DFS compared with NLR, PLR and fibrinogen level. Our result also showed that the c-index values for OS and DFS were both greater in TNM + F-PLR than those in TNM stage alone.

Conclusions

In conclusion, F-PLR score is a predictive biomarker for prognosis in patients with ESCC.

Peer Review reports

Background

Esophageal cancer is one of the most aggressive cancers in gastrointestinal tract cancers and it is the fourth leading cause of cancer death in China [1, 2]. Esophageal squamous cell carcinoma (ESCC) is the major histological type of esophageal cancer in Asian countries, including Japan and China [3]. Although great improvement has been made in the diagnosis and treatment of ESCC in recent years, the clinical outcome of patients still remains poor [4]. Therefore, identifying a simple and dependable biomarker that could distinguish ESCC patients with high risk of tumor progression and poor prognosis is extremely urgent.

Growing evidence has showed the tumor progression and prognosis are determined not only by features of tumor but also host inflammation response [5, 6]. Recently, evidence has increasingly shown that the inflammatory biomarkers including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) has been reported to be a prognostic predictor in cancers [7, 8], including ESCC [9,10,11]. On the other hand, fibrinogen is a pro-inflammatory protein synthesized by hepatocytes and converted to fibrin in response to infection, tissue injury, or inflammation [12, 13], and it has been reported to play an important role in the coagulation cascade, which takes a key role in the process of tumor progression and metastasis [14]. In addition, some studies reported that plasma fibrinogen levels were significantly associated with tumor development and prognosis in several types of cancers [15, 16], including ESCC [17, 18]. Previous study by Yang et al. has demonstrated that PLR was a superior prognostic predictor compared with NLR in ESCC patients [19]. Therefore, we proposed a novel prognostic biomarker based on a combination of plasma fibrinogen levels and PLR in patients with cancers. Until now, the clinical value of the combined score of fibrinogen levels and PLR (F-PLR score) in blood specimens from ESCC patients has not been reported.

The aim of this present study was to explore the association of the F-PLR score and clinicopathological features. We also assessed the prognostic significance of these biomarkers (including F-PLR score, NLR, PLR and plasma fibrinogen) and compared their prognostic capacity in ESCC.

Materials and methods

Patients

We reviewed the data of ESCC patients who underwent radical surgery at the Tianjin Medical University Cancer Institute and Hospital between May 2005 and December 2021. The criteria for patient selection were as follows: (1) Pathologic diagnosis of primary ESCC; (2) no history of preoperative adjuvant therapy; (3) preoperative blood routine result and fibrinogen levels obtained within 2 weeks before operation; (4) no history of neoadjuvant therapy or preoperative anti-inflammatory treatment, or long-term use of anticoagulant drugs. Patients with multiple cancers and patients who received palliative resection were excluded in our study. The following information was recorded for all ESCC patients: age, gender, operation date, tumor location, max tumor diameter, tumor differentiation, TNM stage, depth of tumor invasion, status of lymph node metastasis and preoperative laboratory data (including neutrophil, lymphocyte and platelet counts in routine blood test and fibrinogen levels in blood clotting function test). Patients were classified and staged based on the 8th edition of the AJCC/UICC tumor-node-metastasis (TNM) classification system. All ESCC patients were followed-up every 3 to 6 months after operation by regular clinical examinations, such as tumor marker tests (CEA, SCC, Cyfra21-1), ultrasonography, and computed tomography. The median follow-up period was 44 months (range, 2-107 months).

Statistical analysis

Association between the fibrinogen levels and the PLR (F-PLR) score and clinicopathological features were assessed using the Chi-squared test. Survival rates, including overall survival (OS) and disease-free survival (DFS), were assessed using Kaplan–Meier method with the log-rank tests. Univariate analysis was used to determine the association between the prognostic factors and survival rates. Significant prognostic factors for survival rates in univariate analysis were included in the multivariate analyses using the Cox proportional hazards model with input method.

We assessed the predictive prognostic ability of different classification by measuring discrimination, which is the ability to distinguish between high-risk and low-risk patients. The method of Harrell’s concordance index (c-index) was used to evaluated the discrimination and the optimal cut-off values of biomarkers [20, 21]. The maximum c-index value was 1.0 and a higher c-index indicated a more desirable model for predicting the prognosis.

Statistical analyses were performed using SPSS software version 22.0 (SPSS, Chicago, IL, USA) and STATA software (version 18.0, Stata Corporation, College Station, TX, USA). All statistical analyses were two-sided, and a p-value of less than 0.05 was considered statistically significant.

Result

Optimal cut-off values of biomarkers

Until now, controversy still exists on the optimal cut-off values of NLR, PLR and fibrinogen for predicting prognosis in ESCC. In our study, we use the method of c-index to determine the optimal cut-off values of these biomarkers. The results showed that the c-index values were maximum for OS (and/or DFS) when NLR, PLR and fibrinogen were 1.6, 126, and 3.8, respectively (Table S1). For further analysis, we separated ESCC patients into two groups (NLR < 1.6 and ≥ 1.6; PLR < 126 and ≥ 126; fibrinogen < 3.8 g/L and ≥ 3.8 g/L).

Clinicopathological factors and F-PLR score

The F-PLR score was divided into three groups based on each cut-off value of fibrinogen and PLR as follows; F-PLR score of 2: with high fibrinogen level (≥ 3.8 g/L) and high PLR (≥ 126), F-PLR score of 1: with one of these hematological abnormalities, and F-PLR score of 0: with neither high fibrinogen level nor high PLR. We enrolled 506 patients with ESCC in this study, including 413 (81.0%) males and 93 (19.0%) females. The median age of these patients was 61 years (range, 33–92). The patients’ baseline characteristics and clinicopathological features divided by F-PLR score were described in Table 1.

Table 1 Relationship between clinicopathological features and F-PLR score in ESCC
Full size table

Our result indicated that the high F-PLR score was significantly associated with longer tumor length and deeper depth of tumor invasion (p < 0.01, Table 1). There was no significant association between F-PLR score and age, gender, tumor location, tumor differentiation, lymph node metastasis, TNM stage, status of adjuvant chemotherapy (p > 0.05, Table 1).

Prognosis and F-PLR score

In our study, the methods of Kaplan-Meier with log-rank tests and univariate analysis were used to explore the association of prognosis and biomarkers. The result of Kaplan-Meier curve indicated that high NLR, high PLR, high plasma fibrinogen level and high F-PLR score were significantly associated with poor OS and DFS (p < 0.05, Fig. 1, Figure S1).

Fig. 1
figure 1

Kaplan-Meier curves of overall survival and disease-free survival in ESCC patients based on F-PLR score

Full size image

The result of univariate analysis showed that longer tumor length, depth of tumor invasion, lymph node metastasis, TNM stage, NLR, PLR, fibrinogen level and F-PLR score were significantly associated with OS and DFS (p < 0.05, Table 2). Moreover, Cox multivariable analysis showed that F-PLR score was an independent prognostic factor for OS (p = 0.002) and DFS (p = 0.003, Table 2).

Table 2 Univariate and multivariate survival analyses of OS and DFS in patients with ESCC
Full size table

Prognostic ability of F-PLR score

In this study, we used the method of c-index to compare the prognostic value of these biomarkers. The result indicated that F-PLR score presented the maximum c-index value for OS and DFS compared with NLR, PLR and fibrinogen level (no matter whether they were regarded as dichotomous variables or continuous variables). On the other hand, we also calculated the c-index value of TNM stage combined with F-PLR score (TNM + F-PLR) and of TNM stage alone for OS and DFS. Our result demonstrated that the c-index values were greater (OS: 0682 vs. 0.644; DFS: 0.668 vs. 0.638) in TNM + F-PLR than those in TNM stage alone (Fig. 2).

Fig. 2
figure 2

Comparison of the c-index values for biomarkers on overall survival and disease-free survival

Full size image

Discussion

In this study, we retrospectively reviewed a cohort of ESCC patients in our institution. Our result indicated that high F-PLR score was significantly related with advanced tumor features, including longer tumor length and deeper depth of tumor invasion. On the other hand, the result of Kaplan-Meier with log-rank tests and univariate analysis both showed that high F-PLR score were significantly associated with poor OS and DFS. In addition, Cox multivariable analysis indicated that F-PLR score was an independent prognostic factor in ESCC. These results demonstrated that F-PLR score was a predictor of prognosis and was significantly associated with advanced tumor features in ESCC patients. To the best of our knowledge, this is the first report to study the clinicopathological and prognostic value of F-PLR score in patients with ESCC.

There were several reasons to explain the association of F-PLR score and poor prognosis. First, Platelets and fibrinogen together plays a key role in cancer progression (including growth, invasion and metastasis) by promoting cancer neovascularization and supporting the sustained adhesion of cancer cells [22, 23], Palumbo et al. found that platelet-fibrin (ogen) axis may increase metastatic potential by impeding natural killer cell-mediated elimination of cancer cells [24]. While lymphocytes are the important components of the immune system and can kill cancer cells and prevent cancer progression [25]. Thrombocytosis, hyperfibrinogenemia and low lymphocyte count were proved to be significantly associated with poor prognosis in different types of cancer [26,27,28,29]. Therefore, this may partly explain why high F-PLR score was significantly related with poor prognosis in ESCC. On the other hand, the result showed that high F-PLR score was significantly related with advanced tumor features. Therefore, high F-PLR score may be associated with the extent of cancer progression and consequently may affect the prognosis of ESCC patients. However, we should note that cancers usually induce a hypercoagulable state in the host and may results in thrombocytosis and hyperfibrinogenemia [30]. Whether high F-PLR score is a cause or consequence of cancer progression still remains unknown and needs to be confirmed in the future.

Based on previous reports, we hypothesized that the combined score of fibrinogen levels and PLR these two markers may be a better indicator for prognosis in ESCC at the beginning of the study. The results bear out our supposition. In this study, the method of c-index was used to compare the prognostic capacity of these biomarkers. Our result indicated that F-PLR score presented the greater c-index values for OS and DFS compared with NLR, PLR and fibrinogen. In addition, we found that the c-index values for OS and DFS were greater in TNM + F-PLR than those in TNM stage alone, indicating that TNM + F-PLR had better prognostic ability than TNM stage alone. Therefore, F-PLR score may provide an additional biomarker in the current TNM stage system and increase the prognostic accuracy in ESCC.

Until now, there is no uniform method to determine an optimal cut-off value of these biomarkers suitable for all patient cohorts. In our study, c-index, which is a commonly used method to evaluate the predictive prognostic capacity of models, was used to explore the optimal cut-off value among these ESCC patients. However, whether this cut-off value determined by the patient cohort in our institution can be applied to other independent patient cohorts needs to be further confirmed.

There are several limitations in our study. First, the data of these patients with ESCC was reviewed retrospectively and all patients are from only one single institution. Second, because of the lack of relevant data, we did not explore the clinicopathological and prognostic value of other inflammatory biomarkers, such as acute-phase proteins and procalcitonin. Third, we did not analyze the impact of comorbidities (diabetes, coronary heart disease, hypertension, thromboembolic disease et al.) or other unmeasured variables on the F-PLR score and patient outcomes due to the lack of relevant information.

Conclusions

In summary, F-PLR score has clinical potential as a predictive biomarker for prognosis in patients with ESCC.

Data availability

The datasets used during the current study are available from the corresponding author on reasonable request.

References

  1. Li J, Xu JG, Zheng YD, Gao Y, He SY, Li H, et al. Esophageal cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2021;33(5):535–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–91.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Yang S, Lin S, Li N, Deng Y, Wang M, Xiang D et al. Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea. J Hematol Oncol. 2020; 13(1).

  4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-a Cancer J Clin. 2021;71(3):209–49.

    Article  Google Scholar 

  5. Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10(1):5421.

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  6. Liu CH, Chen Z, Chen K, Liao FT, Chung CE, Liu X, et al. Lipopolysaccharide-mediated chronic inflammation promotes Tobacco Carcinogen-Induced Lung Cancer and determines the efficacy of Immunotherapy. Cancer Res. 2021;81(1):144–57.

    Article  CAS  PubMed  Google Scholar 

  7. Hu C, Bai Y, Li J, Zhang G, Yang L, Bi C, et al. Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer. BMC Urol. 2020;20(1):57.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gawinski C, Holdakowska A, Wyrwicz L. Correlation between lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and Extramural Vascular Invasion (EMVI) in locally advanced rectal Cancer. Curr Oncol. 2022;30(1):545–58.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nat Commun. 2022;13(1):857.

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  10. Wang C, Tong J, Tang M, Lu Y, Liang G, Zhang Z, et al. Pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic factors and reference markers of Treatment options for locally advanced squamous cell carcinoma located in the Middle and Upper Esophagus. Cancer Manag Res. 2021;13:1075–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chen LC, Li SH, Lo CM, Chen YH, Huang SC, Wang YM, et al. Platelet-to-lymphocyte ratio is an independent prognosticator in patients with esophageal squamous cell carcinoma receiving esophagectomy. J Thorac Dis. 2019;11(11):4583–90.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Tennent GA, Brennan SO, Stangou AJ, O’Grady J, Hawkins PN, Pepys MB. Human plasma fibrinogen is synthesized in the liver. Blood. 2007;109(5):1971–4.

    Article  CAS  PubMed  Google Scholar 

  13. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemostasis: JTH. 2005;3(8):1894–904.

    Article  CAS  PubMed  Google Scholar 

  14. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.

    Article  ADS  CAS  PubMed  Google Scholar 

  15. Zhang K, Xu Y, Tan S, Wang X, Du M, Liu L. The association between plasma fibrinogen levels and lung cancer: a meta-analysis. J Thorac Dis. 2019;11(11):4492–500.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kuroda K, Tasaki S, Asakuma J, Horiguchi A, Ito K. Preoperative risk stratification using plasma fibrinogen levels can predict lymphovascular invasion and poor prognosis in patients with upper urinary tract urothelial carcinoma. Mol Clin Oncol. 2021;14(5):102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wang J, Huang D, Wang Y, Yuan Q, Chen X, Cheng Y. Pretreatment plasma fibrinogen and serum albumin levels predict therapeutic efficacy of concurrent radiochemotherapy for esophageal squamous cell cancer. Front Oncol. 2022;12:1021214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hoshino S, Matsuda S, Kawakubo H, Yamaguchi S, Nakamura K, Aimono E, et al. Elevation of the prognostic factor plasma fibrinogen reflects the immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma. Ann Surg Oncol. 2022;29(11):6894–904.

    Article  PubMed  Google Scholar 

  19. Yang Y, Xu H, Zhou L, Deng T, Ning T, Liu R, et al. Platelet to lymphocyte ratio is a predictive marker of prognosis and therapeutic effect of postoperative chemotherapy in non-metastatic esophageal squamous cell carcinoma. Clin Chim Acta. 2018;479:160–5.

    Article  CAS  PubMed  Google Scholar 

  20. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.

    Article  PubMed  Google Scholar 

  21. Newson RB. Comparing the predictive powers of survival models using Harrell’s C or Somers’ D. Stata J. 2010;10(3):339–58.

    Article  Google Scholar 

  22. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126(5):582–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34(1):43–62.

    Article  CAS  PubMed  Google Scholar 

  24. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178–85.

    Article  CAS  PubMed  Google Scholar 

  25. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411(6835):380–4.

    Article  ADS  CAS  PubMed  Google Scholar 

  26. Zhao W, Wang P, Jia H, Chen M, Gu X, Liu M, et al. Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care? BMC Cancer. 2017;17(1):514.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer RJ, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006;107(8):1793–800.

    Article  PubMed  Google Scholar 

  28. Feng Z, Wen H, Bi R, Duan Y, Yang W, Wu X. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. BMC Cancer. 2016;16:43.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Shu YJ, Weng H, Bao RF, Wu XS, Ding Q, Cao Y, et al. Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study. BMC Cancer. 2014;14:566.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3(1):27–34.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Department of Gastrointestinal Oncology of Tianjin Medical University Cancer Institute and Hospital.

Funding

This work was funded by Tianjin Key Medical Discipline (Specialty) Construction Project (Grant No. TJYXZDXK-009 A), National Natural Science Foundation of China (Grant No. 82103677), and National Science and Technology Major Projects of China (Grant No. 2019ZX09732-001).

Author information

Author notes

  1. Yuchong Yang, Hui Tan and Yao Lu contributed equally to this work.

Authors and Affiliations

  1. Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Huanhuxi Road, Tiyuanbei, Hexi District, 300060, Tianjin, China

    Yuchong Yang, Yao Lu, Ming Bai, Xia Wang, Shaohua Ge, Tao Ning, Le Zhang, Zhi Ji, Jingjing Duan, Yansha Sun, Feixue Wang, Rui Liu, Hongli Li & Ting Deng

  2. Department of Surgical Oncology and General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

    Hui Tan & Jipeng Mei

  3. Tianjin University of Traditional Chinese Medicine, Tianjin, China

    Mengqi Zhang

Authors
  1. Yuchong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jipeng Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mengqi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ming Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shaohua Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tao Ning
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Le Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Zhi Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jingjing Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yansha Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Feixue Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Rui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hongli Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Ting Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceived and designed the analysis: Yuchong Yang, Ting Deng; Collected the data: Yuchong Yang, Yao Lu, Ming Bai, Xia Wang, Jipeng Mei; Contributed data or analysis tools: Hui Tan, Shaohua Ge, Tao Ning, Le Zhang, Zhi Ji; Performed the analysis: Jingjing Duan, Yansha Sun, Feixue Wang, Mengqi Zhang; Wrote the manuscript: Yuchong Yang, Hui Tan, Yao Lu; Revised the manuscript: Rui Liu, Hongli Li, Ting Deng.

Corresponding author

Correspondence to Ting Deng.

Ethics declarations

Ethics approval and consent to participate

The study was a retrospective study and did not intervene in patient treatment. All data was obtained in accordance with the Declaration of Helsinki. Contacting patients to obtain consent would pose a greater risk than the waiver due to the retrospective nature of the study. Ethical exemptions were granted and written informed consent was waived by the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, Y., Tan, H., Lu, Y. et al. Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma. BMC Cancer 24, 249 (2024). https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-024-11968-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-024-11968-6

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us